Le 17 septembre 2026, le Comit\u00e9 des m\u00e9dicaments \u00e0 usage humain (CHMP) de l\u2019Agence europ\u00e9enne des m\u00e9dicaments (EMA) a adopt\u00e9 un avis positif recommandant l\u2019octroi d\u2019une autorisation de mise sur le march\u00e9 pour le m\u00e9dicament Povofortay, destin\u00e9 au traitement de l\u2019hidrad\u00e9nite suppur\u00e9e. Le demandeur est la soci\u00e9t\u00e9 Incyte Biosciences Distribution B.V.<\/p>\n
Povofortay sera disponible sous forme de comprim\u00e9s pellicul\u00e9s dos\u00e9s \u00e0 45 mg et 75 mg. La substance active est le povorcitinib, un inhibiteur de la Janus kinase 1 (JAK1), sans code ATC attribu\u00e9 \u00e0 ce stade. En inhibant la signalisation des cytokines d\u00e9pendante de JAK1 (notamment IL\u20116, IL\u20112 et IL\u201122), ce m\u00e9dicament vise \u00e0 emp\u00eacher l\u2019activation des cellules immunitaires et \u00e0 r\u00e9duire l\u2019inflammation cutan\u00e9e et syst\u00e9mique associ\u00e9e \u00e0 l\u2019hidrad\u00e9nite suppur\u00e9e.<\/p>\n
Le principal b\u00e9n\u00e9fice mis en avant est la r\u00e9duction du nombre de l\u00e9sions cutan\u00e9es et de la douleur chez des patients atteints d\u2019hidrad\u00e9nite suppur\u00e9e mod\u00e9r\u00e9e \u00e0 s\u00e9v\u00e8re, d\u00e9j\u00e0 trait\u00e9s par une th\u00e9rapie anti\u2011TNF, par rapport au placebo. Les effets ind\u00e9sirables les plus fr\u00e9quents sont les infections des voies respiratoires sup\u00e9rieures, la folliculite, les infections urinaires, l\u2019hyperlipid\u00e9mie, les c\u00e9phal\u00e9es, l\u2019acn\u00e9 et l\u2019augmentation de la cr\u00e9atine phosphokinase sanguine.<\/p>\n
L\u2019indication retenue est le traitement de l\u2019hidrad\u00e9nite suppur\u00e9e (acn\u00e9 inversa) active mod\u00e9r\u00e9e \u00e0 s\u00e9v\u00e8re chez l\u2019adulte ayant une r\u00e9ponse insuffisante, une intol\u00e9rance ou une contre-indication \u00e0 un traitement par anti\u2011TNF. Le traitement par Povofortay doit \u00eatre initi\u00e9 et supervis\u00e9 par des m\u00e9decins exp\u00e9riment\u00e9s dans le diagnostic et la prise en charge de cette pathologie. Les recommandations d\u00e9taill\u00e9es d\u2019utilisation seront pr\u00e9cis\u00e9es dans le r\u00e9sum\u00e9 des caract\u00e9ristiques du produit (RCP), qui sera publi\u00e9 sur le site de l\u2019EMA dans toutes les langues officielles de l\u2019Union europ\u00e9enne apr\u00e8s la d\u00e9cision formelle d\u2019autorisation de mise sur le march\u00e9 par la Commission europ\u00e9enne. (contenu r\u00e9sum\u00e9 en fran\u00e7ais par l’IA)\u00a0\u200bLire la Suite<\/a><\/p>","protected":false},"excerpt":{"rendered":" Le 17 septembre 2026, le Comit\u00e9 des m\u00e9dicaments \u00e0 usage humain (CHMP) de l\u2019Agence europ\u00e9enne des m\u00e9dicaments (EMA) a adopt\u00e9 un avis positif recommandant l\u2019octroi d\u2019une autorisation de mise sur […]<\/p>\n","protected":false},"author":1,"featured_media":17698,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[7],"tags":[257,227,226],"class_list":["post-17904","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicaments-et-produits-de-sante","tag-ema","tag-ia","tag-sources-etrangeres"],"_links":{"self":[{"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/posts\/17904","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=17904"}],"version-history":[{"count":0,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/posts\/17904\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/media\/17698"}],"wp:attachment":[{"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=17904"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=17904"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=17904"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}